Literature DB >> 22228428

Purified vitexin compound 1 suppresses tumor growth and induces cell apoptosis in a mouse model of human choriocarcinoma.

Zhihui Tan1, Yi Zhang, Jun Deng, Guangyao Zeng, Yu Zhang.   

Abstract

OBJECTIVE: In our previous study, we had isolated a series of lignan compounds, termed vitexins, from the seed of Chinese herb Vitex negundo and found broad antitumor activities of these compounds in many cancer xenograft models and cell lines. This study was aimed to determine the antitumor effect of purified vitexin compound 1 (VB1) on choriocarcinoma in vitro and in vivo.
MATERIALS AND METHODS: The severe combined immunodeficiency mouse model of choriocarcinoma was established to investigate the in vivo effect of VB1. Its effect on proliferation and apoptosis in JEG-3 cell line was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, colony formation assay and flow cytometry, respectively. The expression of caspase-3, Bcl-2, and some molecules involved in the mammalian target of rapamycin (mTOR) signaling was detected by Western blot.
RESULTS: Vitexin compound 1 significantly inhibited the growth of choriocarcinoma in severe combined immunodeficient mice and reduced the serum β-human chorionic gonadotropin level. Vitexin compound 1 inhibited cell proliferation, induced apoptosis, and inhibited the mTOR signaling in JEG-3 cell line.
CONCLUSION: Vitexin compound 1 could inhibit choriocarcinoma via inducing cell apoptosis and suppressing the mTOR pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228428     DOI: 10.1097/IGC.0b013e31823de844

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

Review 1.  Vitex negundo and its medicinal value.

Authors:  Balraj Singh Gill; Richa Mehra; Sanjeev Kumar
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

2.  Protective effect of vitexin compound B-1 against hypoxia/reoxygenation-induced injury in differentiated PC12 cells via NADPH oxidase inhibition.

Authors:  Zhong-Bao Yang; Bin Tan; Ting-Bo Li; Zheng Lou; Jun-Lin Jiang; Ying-Jun Zhou; Jie Yang; Xiu-Ju Luo; Jun Peng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-20       Impact factor: 3.000

3.  Central Antinociceptive and Mechanism of Action of Pereskia bleo Kunth Leaves Crude Extract, Fractions, and Isolated Compounds.

Authors:  Carolina Carvalho Guilhon; Ikarastika Rahayu Abdul Wahab; Fabio Boylan; Patricia Dias Fernandes
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-27       Impact factor: 2.629

Review 4.  The Potential of Plant Phenolics in Prevention and Therapy of Skin Disorders.

Authors:  Magdalena Działo; Justyna Mierziak; Urszula Korzun; Marta Preisner; Jan Szopa; Anna Kulma
Journal:  Int J Mol Sci       Date:  2016-02-18       Impact factor: 5.923

5.  Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway.

Authors:  Jin-Dan He; Zhen Wang; Shi-Peng Li; Yan-Jie Xu; Yao Yu; Yi-Jie Ding; Wen-Li Yu; Rong-Xin Zhang; Hai-Ming Zhang; Hong-Yin Du
Journal:  Oncotarget       Date:  2016-12-20

6.  Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels.

Authors:  Nian Liu; Kuan Song Wang; Min Qi; Ying Jun Zhou; Guang Yao Zeng; Juan Tao; Jian Da Zhou; Jiang Lin Zhang; Xiang Chen; Cong Peng
Journal:  J Exp Clin Cancer Res       Date:  2018-11-06

7.  Vitexin Inhibits Gastric Cancer Growth and Metastasis through HMGB1-mediated Inactivation of the PI3K/AKT/mTOR/HIF-1α Signaling Pathway.

Authors:  Peng Zhou; Zi-Han Zheng; Tao Wan; Jie Wu; Chuan-Wen Liao; Xue-Jun Sun
Journal:  J Gastric Cancer       Date:  2021-12-31       Impact factor: 3.720

8.  Vitexin confers HSF-1 mediated autophagic cell death by activating JNK and ApoL1 in colorectal carcinoma cells.

Authors:  Monika Bhardwaj; Souren Paul; Rekha Jakhar; Imran Khan; Ji In Kang; Ho Min Kim; Jong Won Yun; Seon-Jin Lee; Hee Jun Cho; Hee Gu Lee; Sun Chul Kang
Journal:  Oncotarget       Date:  2017-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.